NCT03802851Recruiting
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
Source: ClinicalTrials.gov · Last updated 13 Jul 2026
Brief summary (registry, in English)
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate cancer.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 3 Jan 2019
- Start date
- 19 Sept 2019
- Primary completion date
- 31 Jan 2030
- Lead sponsor
- University of Kansas Medical Center
- Diseases
- Prostate cancer
- NCT number
- NCT03802851
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 19 Sept 2019 to the primary completion date, 31 Jan 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with prior treatment for prostate cancer are not eligible.
- Patients with any type of prior prostate surgery (minimally invasive, endoscopic, or otherwise) including prior transurethral resection of the prostate (but excluding prior prostate biopsy) are ineligible.
- Patients who are enrolled in other surgical or international trials at the time of this study are not eligible
Other illness
- Patients who have a diagnosis of bladder cancer are not eligible.
- Patients with known metastatic prostate cancer are ineligible
Age
- Patients who are under 18 years of age are not eligible
Who the study is looking for
- Patients must be 18 years of age or older
- Patients must have bothersome lower urinary tract symptoms (LUTS), defined by American Urological Association Symptom Score (AUA SS) of greater than or equal to 15 and/or as defined by a post-void residual of greater than or equal to 350mL and/or as defined by catheter dependence
- Patients must be diagnosed with prostate cancer by pathological tissue analysis
- Patients must have elected for radiation with androgen deprivation therapy as the primary treatment modality for their prostate cancer
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kansas Health System Coordinator of this site? Confirm its status | Kansas City | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.